Tata Capital arm injects USD 20 million in Orbicular Pharmaceutical Technologies

According to the statement, Tata Capital Healthcare Fund II has made the investment in the Hyderabad-based specialty pharmaceutical company and the proceeds will be utilised for accelerating product development,

As per PTI, the statement said the USD 60 billion specialty generics industry is expanding rapidly driven by increasing demand for cost-effective alternatives to complex and high-cost branded medications, and Orbicular has a pipeline of niche products in the specialty generics space catering to the demand.

"This investment reinforces our fund's core philosophy of identifying the big shifts in the industry and being a "capital plus" partner to our companies," Visalakshi Chandramouli, Managing Partner, Tata Capital Healthcare Fund said.

"Having positioned Orbicular as a differentiated specialty pharmaceutical company in the complex generics space, the investment will further strengthen our global partnerships," the company's Managing Director M S Mohan.

The Tata Capital Healthcare Fund (‘TCHF’) is a growth oriented private equity fund focused on the healthcare and lifesciences sector in India. The fund is sponsored by Tata Capital Limited, a subsidiary of Tata Sons Limited. TCHF has raised ~ US$ 200 million across two funds - TCHF I (2012) and TCHF II (2022). Across both the funds, TCHF has invested in 16 companies, and has successfully exited 6 companies thus far.